Mark S. Shahin
Expertise in
19
conditions

Dr. Mark S. Shahin

Oncology | Obstetrics and Gynecology
1203 Langhorne-Newtown Road, Suite 135, 
Langhorne, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Referral may be required
Expertise in
19
conditions
1203 Langhorne-Newtown Road, Suite 135, 
Langhorne, PA 

Overview

Mark Shahin is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Langhorne, Pennsylvania.

Dr. Shahin is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy.

Dr. Shahin is board certified in Gynecologic Oncology, American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 29 clinical trials.

Graduate Institution

Northwestern University Medical School

Residency

McGaw Medical Center of Northwestern University

Specialties

Oncology
Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in PA

Board Certifications

Gynecologic Oncology, American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology

Fellowships

University of Iowa

Hospital Affiliations

St. Mary Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Alliance Cancer Specialists
1203 Langhorne-Newtown Road, Suite 135, Langhorne, PA 19047

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: April 07, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
View 9 Less Clinical Trials

44 Total Publications

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Journal: Gynecologic oncology
Published: September 17, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Hossein Borghaei
Oncology
Expertise in
18
conditions
Dr. Hossein Borghaei
Oncology

Fox Chase Cancer Center Medical Group Inc

333 Cottman Ave, 
Philadelphia, PA 
 (84.8 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances

Hossein Borghaei is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology
Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology

Jefferson Medical Oncology-Honickman Center

1101 Chestnut St Fl 14, 
Philadelphia, PA 
 (83.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 25 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (81.4 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Mark S. Shahin

How do I make an appointment with Dr. Mark S. Shahin?

You can book an appointment with Dr. Mark S. Shahin by calling their office at 215-750-5050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark S. Shahin a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark S. Shahin is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark S. Shahin specialize in?

While Dr. Mark S. Shahin is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Cervical Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mark S. Shahin participate in research or clinical trials?

Yes. Dr. Mark S. Shahin has published 44 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Mark S. Shahin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark S. Shahin accept my insurance?

Dr. Mark S. Shahin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-750-5050 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shahin's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 52 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile